100516 Federal Register / Vol. 89, No. 239 / Thursday, December 12, 2024 / Notices 

e. Prescribes procedures to govern the 

routing and review, within the 

Department, of material relating to 

proposed Federal legislation. 

9. National Complex Litigation and 

Investigation Division (NCLID). NCLID 

provides legal services to all agencies 

and offices within the Department, as 

directed by the General Counsel. NCLID 

provides legal services in connection 

with complex litigation or anticipated 

complex litigation by or against the 

Department. Such litigation may 

include cases for which other OGC 

divisions or regional offices request 

NCLID participation, cases spanning 

multiple OGC divisions or regional 

offices, or cases outside the scope of 

other OGC divisions or regional offices. 

NCLD administers the OGC-wide ediscovery program and coordinates the 

use of e-discovery technology with 

agencies and offices within the 

Department. 

10. Public Health Division (Ph.D.). 

Ph.D. provides legal services to all 

Public Health Service agencies (except 

to FDA) and their programs, including 

the Office of the Surgeon General and 

the Commissioned Corps of the U.S. 

Public Health Service. Represented 

Public Health Service agencies include, 

but are not limited to: (i) the Office of 

the Assistant Secretary for Health, and 

its various programs; (ii) the Office of 

the Secretary’s Office of Minority 

Health; (iii) the Centers for Disease 

Control and Prevention; (iv) the 

National Institutes of Health; (v) the 

Health Resources and Services 

Administration; (vi) the Indian Health 

Service; (vii) the Substance Abuse and 

Mental Health Services Administration; 

(viii) the Agency for Healthcare 

Research and Quality, (ix) the 

Administration for Strategic 

Preparedness and Response, and (x) the 

Agency for Toxic Substances and 

Disease Registry. 

Subsection C. Functions and 

Responsibilities of the OGC Regional 

Offices 

An OGC regional office is located in 

each of the ten HHS regions, each of 

which is led by a Regional Director 

appointed by the Secretary. The Chief 

Counsel of each Region is the 

Department’s legal representative in that 

Region. Regional offices within OGC 

provide a full range of legal services, 

subject to the professional supervision 

and direction of the General Counsel 

and the designated Deputy General 

Counsel. This includes providing legal 

advice and representation in 

administrative and judicial litigation 

regarding programs operated by the 

Centers for Medicare and Medicaid 

Services, the Administration for 

Children and Families, the 

Administration for Community Living, 

and Public Health Service agencies 

including the Indian Health Service, the 

Health Resources and Services 

Administration, the Substance Abuse 

and Mental Health Services 

Administration, and the Centers for 

Disease Control and Prevention; 

providing legal services to the Office for 

Civil Rights, including advice and 

representation in administrative and 

judicial litigation with respect to the 

enforcement of civil rights laws and the 

Health Insurance and Portability and 

Accountability Act of 1996 (Social 

Security Act sec. 1171 et seq.); and 

providing legal advice and 

representation in administrative and 

judicial litigation relating to business 

management activities and 

administrative operations, such as 

employment and labor relations, 

information disclosure and privacy, 

Federal tort claims, and suspensions, 

disallowances, and other recoveries of 

payments made under HHS programs, of 

HHS components operating in their 

regions. 

The HHS regional offices are located 

in the following cities and cover all 

States and territories of the United 

States, as well as three independent 

states in the Pacific. 

1. OGC Region 1—Boston covers 

Connecticut, Maine, Massachusetts, 

New Hampshire, Rhode Island, and 

Vermont. 

2. OGC-Region 2—New York City 

covers New York, New Jersey, Puerto 

Rico, and the Virgin Islands. 

3. OGC Region 3—Philadelphia covers 

Delaware, Maryland, Pennsylvania, 

Virginia, West Virginia, and the District 

of Columbia. 

4. OGC Region 4—Atlanta covers 

Alabama, Florida, Georgia, Kentucky, 

Mississippi, North Carolina, South 

Carolina, and Tennessee. 

5. OGC Region 5—Chicago covers 

Illinois, Indiana, Ohio, Michigan, 

Minnesota, Wisconsin, and the Bemidji 

Area Office of the Indian Health Service 

(IHS). 

6. OGC Region 6—Dallas covers 

Arkansas, Louisiana, New Mexico, 

Oklahoma, Texas, as well as the 

Albuquerque and Oklahoma City Area 

Offices of the Indian Health Service 

(IHS). 

7. OGC Region 7—Kansas City (MO) 

covers Iowa, Kansas, Missouri, and 

Nebraska. 

8. OGC Region 8—Denver covers 

Colorado, Montana, North Dakota, 

South Dakota, Utah, Wyoming, as well 

as the Great Plains and Billings Area 

Offices of the Indian Health Service 

(IHS). 

9. OGC Region 9—San Francisco 

covers Arizona, California, Hawaii, 

Nevada, Guam, American Samoa, 

Commonwealth of the Northern Mariana 

Islands, the Federated States of 

Micronesia, the Republic of the 

Marshall Islands, the Republic of Palau, 

as well as the California Area, Navajo 

Area, Phoenix Area, and Tucson Area 

Offices of the Indian Health Services 

(IHS). 

10. OGC Region 10—Seattle covers 

Alaska, Idaho, Oregon, Washington, as 

well as the Alaska Area and Portland 

Area Offices of the Indian Health 

Services (IHS). 

Xavier Becerra, 

Secretary, Department of Health and Human 

Services. 

[FR Doc. 2024–29291 Filed 12–11–24; 8:45 am] 

BILLING CODE 4150–26–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Center for Advancing 

Translational Sciences; Notice of 

Closed Meeting 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Center for 

Advancing Translational Sciences Special 

Emphasis Panel; Clinical Trial Readiness for 

Rare Diseases. 

Date: March 6, 2025. 

Time: 10:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Address: National Center for Advancing 

Translational Sciences, National Institutes of 

Health, 9609 Medical Center Drive, 

Rockville, MD 20892 (Video Assisted 

Meeting). 

Contact Person: Alumit Ishai, Ph.D., 

Scientific Review Officer, Office of Grants 

Management and Scientific Review, National 

Center for Advancing Translational Sciences, 

National Institutes of Health, 9609 Medical 

Center Drive, Suite 1E504, Bethesda, MD 

20892, (301) 827–5819, alumit.ishai@nih.gov. 


ddrumheller on DSK120RN23PROD with NOTICES1
Federal Register / Vol. 89, No. 239 / Thursday, December 12, 2024 / Notices 100517 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.859, Pharmacology, 

Physiology, and Biological Chemistry 

Research; 93.350, B—Cooperative 

Agreements; 93.859, Biomedical Research 

and Research Training, National Institutes of 

Health, HHS) 

Dated: December 6, 2024. 

Miguelina Perez, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2024–29160 Filed 12–11–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meeting 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Small 

Business: Health Services and Systems C. 

Date: January 6, 2025. 

Time: 9:00 a.m. to 2:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Address: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Tara Roshell Earl, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 1007C, 

Bethesda, MD 20892, (301) 402–6857 earltr@

mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 

Dated: December 9, 2024. 

Lauren A. Fleck, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2024–29287 Filed 12–11–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meetings 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel RFA Panel; 

Understanding Chronic Conditions 

Understudied Among Women. 

Date: December 13, 2024. 

Time: 9:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Address: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892. 

Meeting Format: Virtual Meeting. 

Contact Person: Amy Kathleen Wernimont, 

Ph.D., Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 6198, 

Bethesda, MD 20892, 301–827–6427, 

amy.wernimont@nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Topics in 

Bacterial-Host Interactions. 

Date: December 13, 2024. 

Time: 10:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Address: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892. 

Meeting Format: Virtual Meeting. 

Contact Person: Bakary Drammeh, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 805–P, 

Bethesda, MD 20892, (301) 435–0000, 

drammehbs@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Member 

Conflict: Topics in Disease Control and 

Applied Immunology. 

Date: December 13, 2024. 

Time: 10:00 a.m. to 7:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Address: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892. 

Meeting Format: Virtual Meeting. 

Contact Person: Jui Pandhare, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Bethesda, MD 

20892, (301) 594–7735, pandharej2@

csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Small 

Business: Topics in Microbial Diagnostics 

and Anti-Infective Prevention Measures. 

Date: December 13, 2024. 

Time: 12:30 p.m. to 6:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Address: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892. 

Meeting Format: Virtual Meeting. 

Contact Person: Bidyottam Mittra, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Bethesda, MD 

20894, (301) 435–4057, bidyottam.mittra@

nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Topics in 

Health Services Research. 

Date: December 18, 2024. 

Time: 3:00 p.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Address: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892. 

Meeting Format: Virtual Meeting. 

Contact Person: Angela D. Thrasher, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 1000J, 

Bethesda, MD 20892, (301) 480–6894, 

thrasherad@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Member 

Conflict: Topics in HIV Virology, 

Immunopathogenesis, and Drug/Vaccine 

Development. 

Date: December 18, 2024. 

Time: 12:00 p.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Address: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892. 

Meeting Format: Virtual Meeting. 

Contact Person: Kenneth M Izumi, Ph.D., 

Scientific Review Officer, NIH Center for 

Scientific Review, 6701 Rockledge Drive, 

MSC 7808, Bethesda, MD 20892, 301–496– 

6980, izumikm@csr.nih.gov. 

This notice is being published less than 15 

days from the meetings’ dates due to 

exceptional circumstances. The technical and 

scientific peer review of applications 

assigned to the above meetings must take 

place urgently so that review evaluations of 

biomedical research applications addressing 

multiple major public health priorities, 

including women’s health research, may be 

submitted to the national advisory councils 

to make timely funding recommendations. If 

the meetings are not held on the December 

13, 2024 and December 18, 2024 dates, 

committee members with the requisite 

scientific expertise will be unable to attend 

due to unresolvable scheduling conflicts. The 

result would be a 6–9 month delay in 

funding and a profound negative impact on 

health-related research. 


ddrumheller on DSK120RN23PROD with NOTICES1